Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

In this episode of the Endocrine Outlook, listeners will hear a conversation with Muthiah Vaduganathan, MD, MPH, a cardiologist at Brigham and Women’s hospital. Vaduganathan was also the member of the writing committee for a recent AHA scientific statement regarding the cardionrenal protective benefits of SGLT2 inhibitors and GLP-1 receptor agonists. 

In this special edition episode of the Endocrine Outlook, you will hear from Professor Hiddo Heerspink.  Heerspink recently presented results of the DAPA-CKD trial at the European Society of Cardiology examining the effects of dapagliflozin (Farxiga) in patients with chronic kidney disease with and without type 2 diabetes. This episode further explores the study and how its results inform the use...

In this episode of the endocrine outlook, you will hear from Dr. Joshua Denson of Tulane University Medicine. In the episode, we discuss the results of a recent study he led examining the effects of metabolic syndrome on outcomes in patients with coronavirus disease 2019 (COVID-19) in a predominantly Black population.  Results of the study suggest individual components on metabolic syndrome were n...

In this episode we will be discussing reaction to topline results from the EMPEROR-REDUCED trial examining the use of empagliflozin for heart failure in patients with and without diabetes with endocrinologist Dr. Robert Busch. Announced on July 30, by Berringer Ingelheim and Lilly,topline  results indicate use of empagliflozin was associated with a decrease in the composite endpoint of CV death an...

In this episode you’ll hear my interview with Dr. Jamie Hartmann-Boyce, senior research fellow and departmental lecturer at the Nuffield Department of Primary Care Health Sciences of University of Oxford. Dr. Hartmann-Boyce is the lead investigator of a recent article published in Diabetes Care providing an overview of potential associations between COVID-19 and diabetes. Published in June, the ar...